

Development of new immune cell therapy for solid tumors

This report is an English translation of part of the report issued on June 30, 2023.
For inquiries concerning the report, please contact info@stock-r.org

[4893 Noile-Immune Biotech Sector : Pharmaceutical]

Fiscal Year	Net sales (mn yen)	YoY (%)	Operating profit (mn yen)	YoY (%)	Ordinary profit (mn yen)	YoY (%)	Profit (mn yen)	YoY (%)	EPS (yen)	BPS (yen)	DPS (yen)
Dec.2021	100	3.1	-767	-	-792	-	-795	-	-20.8	107.3	0.0
Dec.2022	625	6.3x	-106	-	-384	-	-386	-	-9.9	108.5	0.0
Dec.2023 f	319	-49.0	-1,535	-	-1,832	-	-1,834	-	-44.3	-	0.0

Note: Non-consolidated basis. Figures for the fiscal year ending December 2023 are the company's forecasts.

Development of New Immune-Cell Therapy for Solid Tumors

Noile-Immune Biotech, a bio-venture company originating from the National Cancer Center Japan and Yamaguchi University, is developing PRIME CAR-T cell therapy. This is a cancer immunotherapy that treats solid tumors such as stomach cancers and lung cancers by enhancing the function of T cells, which are immune cells. The PRIME technology utilized in this therapy has been developed by the company president and CEO, Koji Tamada, along with his team.

PRIME Technology Responsible for Activating Immune Cells and Accumulate Them to Cancer Sites

PRIME technology is a technique that genetically modifies immune cells to generate substances that activate these cells and induce their accumulation at cancer sites. PRIME CAR-T cell therapy represents the implementation of PRIME technology in CAR-T cells, in which a gene that recognizes cancer antigens is introduced into T cells. The technique demonstrates therapeutic efficacy by accumulating immune cells in the local area of solid tumors. This had proven difficult using conventional CAR-T cell therapy, which targets blood cancers. The technique also activates the patient's own immune cells.

Promote Proprietary Drug Discovery and Joint Pipeline Development with Other Companies

The company has two types of pipelines: a proprietary drug discovery pipeline for the development of PRIME CAR-T cell therapy drugs and a collaborative pipeline for the purpose of providing PRIME technology to other companies' pipelines of cell therapy drugs that are in the process of development. Although the total revenue of the collaborative pipeline is smaller than that of proprietary drug discovery, the funds can be recovered at an early stage in the form of technology fees.

The company has three proprietary drugs in Phase I clinical trials: NIB101 for small cell lung cancer, and two drugs licensed out to Takeda Pharmaceuticals: NIB102 for hepatocellular carcinoma and NIB103 for triple-negative breast cancer (TNBC). NIB101 is expected to be eligible for the early approval system upon confirmation of the drug's efficacy and safety in clinical trials, and derivation is anticipated at that stage.

Financial Statements

Statement of income	Fiscal Year	Dec.2021		Dec.2022		Three mounths to Mar.2023	
		(mn yen)	(%)	(mn yen)	(%)	(mn yen)	(%)
Operating revenue		100	100.0	625	100.0	8	100.0
Project expenses		868	8.7x	732	117.1	277	34.6x
Operating profit		-767	-	-106	-	-269	-
Non-operating income		0	-	5	-	0	-
Non-operating expenses		25	-	283	-	225	-
Ordinary profit		-792	-	-384	-	-493	-
Profit before income taxes		-792	-	-384	-	-493	-
Net profit		-795	-	-386	-	-494	-

Balance sheet	Fiscal Year	Dec.2021		Dec.2022		Mar.2023	
		(mn yen)	(%)	(mn yen)	(%)	(mn yen)	(%)
Current assets		4,225	98.9	4,584	98.8	3,951	98.6
Cash and deposits		4,140	96.9	4,520	97.4	3,871	96.6
Accounts receivable-trade		-	-	-	-	-	-
Inventories		4	0.1	3	0.1	3	0.1
Non-current assets		45	1.1	56	1.2	56	1.4
Property, plant and equipment		-	-	-	-	-	-
Intangible assets		-	-	-	-	-	-
Investments and other assets		45	1.1	56	1.2	56	1.4
Total assets		4,271	100.0	4,641	100.0	4,008	100.0
Current liabilities		80	1.9	335	7.2	196	4.9
Accounts payable - trade		-	-	-	-	-	-
Non-current liabilities		5	0.1	5	0.1	5	0.1
Net assets		4,185	98.0	4,300	92.7	3,806	95.0
Owners' equity		4,180	97.9	4,293	92.5	3,799	94.8

Statement of cash flows	Fiscal Year	Dec.2021	Dec.2022
		(mn yen)	(mn yen)
Cash flows from operating activities		-777	-107
Depreciation		-	-
Cash flows from investing activities		-4	-
Cash flows from financing activities		2,373	487
Dividends paid		-	-
Net increase in cash and cash equivalents		1,592	380
Cash and cash equivalents		4,140	4,520

Note: Non-consolidated

Source: Prepared by Stock Research Center based on the notifiable prospectus.

About Stock Research Center

Stock Research Center is engaged in the preparation of analyst reports, mainly on companies that are not sufficiently covered by analysts, based on a neutral perspective, and broadly disclose the reports to the public with an aim to revitalize the stock market.

Note: Reports prepared by Stock Research Center are created in reference to the Ministry of Economy, Trade and Industry's Guidance for Integrated Corporate Disclosure and Company-Investor Dialogues for Collaborative Value Creation.



■Supporting Members

Tokyo Stock Exchange, Inc.

Nomura Securities Co., Ltd.

KPMG AZSA LLC

Deloitte Touche Tohmatsu LLC

PricewaterhouseCoopers Kyoto

A&A Partners

TAKARA PRINTING CO., LTD.

Japan Securities Dealers Association

SMBC Nikko Securities Inc.

Mizuho Securities Co., Ltd.

ICMG Co., Ltd.

SBI SECURITIES Co., Ltd.

J Trust Global Securities Co., Ltd.

GYOSEI & CO.

PRONEXUS INC.

The Securities Analysts Association of Japan

Daiwa Securities Co. Ltd.

Ernst & Young ShinNihon LLC

Grant Thornton Taiyo LLC

BDO Sanyu

Ichiyoshi Securities Co., Ltd.

Avantia G.P.

Certification by Analysts

Analysts indicated in the reports certify that the content indicated in the report precisely reflects the personal opinions of the analysts on all securities and issuer companies discussed in the report. In addition, it is ensured that the opinions directly or indirectly indicated in the report will have no influence on the analyst's compensation in the past, present, and future upon writing the report.

Disclaimer

- The report is prepared by stock analysts affiliated with the Stock Research Center for the purpose of disclosure to a wide range of investors as reference information and not to recommend or solicit to buy or to sell any particular securities or financial instrument.
- The content and indication of the report is based on disclosed information available publicly and is prepared by adding necessary supplementary information gained through interviews by analysts. The writer of the report is, without exception, prohibited to use insider information, or to acquire such information. The information included in the report is believed to be precise and reliable, but its preciseness is not verified objectively. In addition, the report is not intended to comprehensively include all information required by investors.
- The information included in the report may become outdated due to changes in the financial market, economic environment, etc. There are risks that the prices of stocks featured directly or indirectly in the report will fall below the par value due to fluctuations in stock prices, changes in management/financial conditions of the issuers, fluctuations in exchange rates or interest rates, etc. Past performance does not imply or guarantee future performance.
- The opinions indicated in the report are subject to change without notice and the Stock Research Center has no obligation to update the information or opinions included in the report.
- The Stock Research Center does not bear any responsibility for any results, including direct losses, indirect losses, losses of profit and damages, suffered by investors due to using the report or relying on the report. Final investment decisions shall be made by investors themselves and the sole responsibility concerning the investment lies with the investors that viewed the report.
- The copyright of the report belongs to the Stock Research Center and it may not be copied, reproduced, quoted, etc. in any form without prior consent.